RADICAVA[™] Infusion



Phone: 877.385.0535

Please complete each section of the referral form below and fax to OptiMed along with a copy (front and back) of <u>all</u> the patient's pharmacy and medical insurance cards, the patient's demographic face sheet, and any relevant clinical notes/documents.				
Prescriber nformation	Prescriber: NPI:			
Prescriber nformatio	Phone: Fa	x:	Office Contact:	
Pre	Address:			
Patient Information	Name:	!	DOB:	
	Address:			
	Phone:	2 nd Phone:	SSN: _	
Inf	Primary Language:	Functional Limitations:		
Clinical Information	Diagnosis: □Amyotrophic lateral sclerosis (progressive muscle atrophy) (G12.21) □Other:			
	Weight: □lb □kg Height: □in IV access: Patient has a □PICC □Port □Other:			
	For patients without established access, OptiMed will utilize a PIV for short-term therapy only. PICC or Port recommended for long-term therapy. Patient's first dose of RADICAVA**? Yes No; date of last dose ; prior dose (in mg)			
	Allergies: Latex allergy? □Yes □No			
				Lucex unergy. Elles Elle
	History of sulfite allergy? □Yes □N asthma? □Yes □N			
		o If yes, SCr:	GFR/CrCl·	
	Prior treatments & reason for discontinu			
	Prior treatments & reason for discontinu	action		
	Patient enrolled with SearchLight [™] (RAD	ICAVA™ access program)? □Yes.	ID:	
	Additional Notes:			
	Referring provider's preferred site of care*: □OptiMed Infusion Center □Home Infusion* □OptiMed to determine site of care *Site of care preference is subject to payer limitations, clinical appropriateness, and the availability of servicing providers.			
			ess, and the availability of	
		VA [™] Dosing Regimen	cocutivo deve fallerre	Quantity
Prescription Information	□ Starter Dose: Once daily 60 mg/200 mL, by cessation for 14 days.	60-minute IV infusion for 14 con	secutive days, followed	14 doses (infusions)
	☐ Maintenance Dosing: Once daily 60 mg	/200 ml 60-minute IV infusion fo	or any 10 of 14 days	
	followed by cessation for 14 days.	200 mz, 00 mmate 17 mmasion 16	in any 10 or 11 days,	doses (infusions)
	Site of care: OptiMed Infusion Center (Eligible patients may be transitioned to home infusion following their first dose and as appropriate			
	based on clinical status, patient/provider preference, and payer coverage.)			
	My signature for this prescription also confirms that the treatment(s) indicated on this referral is/are medically necessary. I authorize OptiMed and its representatives to act as an agent of			
Prescriber Signature	mine to initiate and execute the patient's insurance prio			·
	above.			
Pro Sig	Signature:		Date:	

Confidentiality statement: This message is intended only for the individual or institution to which it is addressed. This may contain information, which is confidential, privileged, and/or proprietary. This information may be exempt from disclosure under applicable laws including but not limited to HIPAA. If you are not the intended recipient, please note you are strictly prohibited from distributing, copying, or disseminating this information. If you received this information in error, please notify the sender noted above and destroy all transmitted material.